Boxer, A. L., Moebius, H., Harris, B., Boeve, B. F., Borroni, B., van Swieten, J. C., Grossman, M., Pasquier, F., Frisoni, G. B., Mummery, C. J., Vandenberghe, R., Le Ber, I., Hannequin, D., McGinnis, S. M., Auriacombe, S., Onofrj, M., Goodman, I. J., Riordan, H. J., Wisniewski, G., Hesterman, J., Marek, K., Patzke, H., Koenig, G., & Hilt, D. (n.d.). o4‐02‐01: PHASE 2A RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED TRIAL OF THE HISTONE DEACETYLASE INHIBITOR (HDACI), FRM‐0334, IN ASYMPTOMATIC CARRIERS OF, OR PATIENTS WITH FRONTOTEMPORAL LOBAR DEGENERATION (FTLD) DUE TO, PROGRANULIN GENE MUTATIONS. Alzheimer's & dementia, 15, P1231–P1232. http://access.bl.uk/ark:/81055/vdc_100102561501.0x000013